MedPharm offers new fast track service

Contract development company MedPharm has announced a new fast track service for topical formulation development, including for respiratory delivery. The company offers development services for a variety of OINDP formulations, including MDIs, DPIs, inhalation solutions, and nasal sprays. According to the announcement, the service “produces a safe and stable, but ultimately non-optimized formulation” for proof . . . Read more

Tobramycin inhalation solution gets tentative FDA approval

According to the FDA, the agency has issued a tentative approval of an application by PulmoFlow, Inc. to market tobramycin 300 mg/5 ml inhalation solution. PulmoFlow, Inc. was established in Virginia in 2013. The company’s web site is a single page that says “PulmoFlow is a newly established company currently focused on solutions to improve . . . Read more

Civitas gets $55 million for Phase 3 development of inhaled L-dopa

Civitas Therapeutics has announced that all of its existing investors, plus seven new investors, participated in a $55 million Series C financing round. The company is developing products based on respiratory delivery technology acquired from Alkermes in 2011 and originally developed by AIR. Civitas President and CEO Mark Iwicki commented, “The proceeds from this financing . . . Read more